Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2022.06.24

Sai Life Sciences expands UK footprint four-fold at Alderley Park

Sai Life Sciences expands UK footprint four-fold at Alderley Park

  • India-headquartered molecular research specialists scale UK R&D capabilities in North West
  • Expansion follows rapid business growth – with >50 new hires over the last two years

One of the fastest growing global contract research, development and manufacturing (CRO-CDMO) businesses, Sai Life Sciences, has expanded its existing base at Alderley Park – part of Bruntwood SciTech’s national network of innovation districts – in response to continuing growth.

With a four-fold increase in floor space from 5,000 to 20,000 sq. ft over the last 2 years, Sai Life Sciences’ expansion within the Park’s Mereside Campus includes the addition of a new chemistry and analytical lab, as well as an increase in its fume cupboard provision from 24 to 80. Other capability additions include Integrity 10 parallel screening tool, Open Access GCMS, Open Access Chiral HPLC, Open Access 400 MHz NMR, physical properties analytical equipment (DSC/TGA, XRPD, PSD) and LCMS with accurate mass.

The full-service CRO-CDMO – which works globally with innovative biotech and pharma companies to accelerate the discovery, development and manufacture of complex small molecules for the creation of new medicines –moved to Alderley Park in 2020 to establish its first European hub. Sai Life Sciences’ Alderley Park site has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non GMP delivery, and successful technology transfer to its sites in India for scale-up. Currently, work is underway to also set-up a GMP Kilo Lab at the site by Q4 2022.

Dr Kath Mackay, Director of Life Sciences at Bruntwood SciTech, a partnership between property company Bruntwood and Legal & General, said: “Sai Life Sciences’ rapid expansion since first establishing its European presence here demonstrates just how much of a hotbed Alderley Park, and the UK more broadly, is for high-growth life sciences businesses. Meeting the very real demand that our companies have for grow-on space is something we are committed to meeting, and is why we’re focused on continuing to invest in our lab provision across our network.

“Sai Life Sciences’ expansion also speaks to the value in joining an established, thriving knowledge ecosystem. We see time and again the power in being located within a cluster like Alderley Park – particularly when entering a new market from overseas.”

Tuneer Ghosh, Senior Vice President and Head of CMC Business Development at Sai Life Sciences, said: “Our further UK expansion is testament to the strength of the life science community at Alderley Park. With a growing interest from innovator companies across the UK, Europe and US, this expansion in our facilities along with our top-notch scientific team, will help us better serve the growing demand for high quality process chemistry."

Credit: https://www.alderleypark.co.uk/

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more